Teleflex delivered 32% revenue growth year-over-year and has beaten earnings in 3 of the last 4 quarters, but negative price momentum with a momentum score of only 2.8 out of 10 and falling on-balance-volume signal active distribution, while the stock already sits near its analyst-implied ceiling with negative upside asymmetry.
Thesis pillars
- Revenue Growth Leadership→Stable
- Earnings Beat With One Large Miss→Stable
- Negative Price Momentum Distribution↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Teleflex Incorporated (TFX) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $130.99 — A.R:R 0.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5).
Teleflex designs and supplies single-use medical devices for critical care and surgical applications across Americas, EMEA, and Asia Pacific segments. Revenue comes from selling Arrow-branded catheters, intraosseous systems, interventional cardiology devices, and surgical... Read more
Sell if holding. Analyst target reached at $130.99 — A.R:R 0.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5). Chart setup: No clear chart pattern; technical signals are mixed. Score 6.1/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 45d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-09-13Recent Developments — Teleflex Incorporated
Latest news
- NEWS TFX Looks 27.7% Undervalued on GF Value™ - GuruFocus — GuruFocus positive
- NEWS Teleflex (NYSE:TFX) Raised to "Hold" at UBS Group - MarketBeat — MarketBeat neutral
- NEWS Irenic Capital Management LP Takes $104.06 Million Position in Teleflex Incorporated $TFX - MarketBeat — MarketBeat neutral
- NEWS Teleflex Incorporated $TFX Stake Lessened by ADAR1 Capital Management LLC - MarketBeat — MarketBeat neutral
- NEWS Teleflex (TFX) Is Up 6.3% After OEM Sale And 2026 EPS Upgrade - What's Changed - simplywall.st — simplywall.st positive
Generated 2026-09-14T05:21:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-30Item 5.02MEDIUMJason Weidman appointed as President and CEO effective June 8, 2026, replacing interim CEO Stuart A. Randle, who continues as a Board member. Weidman joins from Medtronic.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·2 ceiling hits
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $130.99 — A.R:R 0.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $125.11. Score 6.1/10, moderate confidence.
Take-profit target: $133.58 (+2.0% upside). Prior stop was $125.11. Stop-loss: $125.11.
Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Leverage penalty (D/E 1.0): -0.5.
Teleflex Incorporated trades at a P/E of N/A (forward 12.0). TrendMatrix value score: 6.5/10. Verdict: Sell.
19 analysts cover TFX with a consensus score of 3.5/5. Average price target: $154.
What does Teleflex Incorporated do?Teleflex designs and supplies single-use medical devices for critical care and surgical applications across Americas,...
Teleflex designs and supplies single-use medical devices for critical care and surgical applications across Americas, EMEA, and Asia Pacific segments. Revenue comes from selling Arrow-branded catheters, intraosseous systems, interventional cardiology devices, and surgical products to hospitals worldwide through a direct sales force and distributors. In December 2025, Teleflex announced $2.0 billion in pending divestitures of its Acute Care, Interventional Urology, and OEM businesses.